Using advanced data analysis to identify genes and drug responses related to diseases.
Official title: Integrating multi-omics datasets to infer phenotype-specific driver genes, regulatory interactions and drug response
Funded at University of North Texas · NIH-10663188 · Data updated 2026-11-12
This study is working on new computer tools that look at a lot of biological information to find out which genes are linked to diseases and how different patients might respond to treatments, all to help create more personalized care for everyone.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of North Texas NIH-funded |
| Lab location | 1 site (Denton, United States) |
| Project start | August 1, 2019 |
| Project end | June 30, 2025 |
| Funding year | 2023 |
| Award (this year) | $349,691 |
| NIH project number | 5R35GM133657-06 |
| Project ID | NIH-10663188 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals with specific genetic conditions or diseases who may benefit from tailored drug therapies.
✕Less likely to help
Patients with conditions that are not influenced by genetic factors or those who do not have access to the necessary multi-omics data may not benefit from this research.
What this research studies
This research focuses on developing innovative computational tools that analyze large datasets from various biological sources, including genetic and environmental information. By integrating these multi-omics datasets, the research aims to uncover specific genes that drive diseases and predict how patients will respond to different medications. The approach leverages recent advancements in technology to handle vast amounts of data, ultimately contributing to more personalized treatment strategies for patients. The tools created will be open-source, allowing for widespread use and collaboration in the scientific community.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized treatment options for patients based on their unique genetic profiles.
How similar studies have gone: Previous research has shown promise in using multi-omics approaches to improve understanding of diseases and drug responses, indicating that this methodology has potential for success.
Where this research is happening
-
University of North Texas
Denton, United States Active
Researchers
- Principal investigator: Bozdag, Serdar — University of North Texas
- Study coordinator: Bozdag, Serdar
Related research
Other NIH-funded projects on the same topics.
-
Cataracts and Work Exposures in Denmark
A large Danish study will look at whether job-related exposures, both chemical and non-chemical, are linked to developing cataracts.
-
New approach to find noninvasive brain networks that predict epilepsy after brain injury
A study aims to identify noninvasive brain biomarkers that can forecast epileptogenesis after brain injury by linking MRI network patterns with EEG signals.
-
Off-the-shelf ADC-NK cell therapy platform for cancer and immune diseases
A universal, ready-to-use natural killer cell therapy armed with antibody-drug conjugates is being developed to target cancers and other diseases.
-
New and better ways to measure kids' exposure to air pollution and traffic
This project looks at how traffic-related air pollution and green space around homes may affect cancer risk in children and uses advanced exposure measurements to better understand these links.
-
Can a single model work for high-resolution 3D genome structure using generalizable methods
A grantfunds researchers to create high-resolution 3D genome models that can work across different cell types using advanced algorithms and machine learning.
-
How tissue stiffness and stretching affect nanoparticle delivery in cancer and other diseases
This grant studies how the physical properties of tissues, like stiffness and stretch, influence how nanoparticles are taken up by cancer-related cells to improve future therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.